Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2015, Article ID 158038, 16 pages
Review Article

Immune Checkpoint Modulation in Colorectal Cancer: What’s New and What to Expect

1Center for Oncological Research, University of Antwerp, 2610 Wilrijk, Belgium
2Department of Pathology, Antwerp University Hospital, 2650 Edegem, Belgium
3Laboratory of Experimental Hematology (LEH), Vaccine and Infectious Disease Institute, University of Antwerp, 2650 Edegem, Belgium

Received 27 July 2015; Accepted 11 October 2015

Academic Editor: Barbara Savoldo

Copyright © 2015 Julie Jacobs et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Colorectal cancer (CRC), as one of the most prevalent types of cancer worldwide, is still a leading cause of cancer related mortality. There is an urgent need for more efficient therapies in metastatic disease. Immunotherapy, a rapidly expanding field of oncology, is designed to boost the body’s natural defenses to fight cancer. Of the many approaches currently under study to improve antitumor immune responses, immune checkpoint inhibition has thus far been proven to be the most effective. This review will outline the treatments that take advantage of our growing understanding of the role of the immune system in cancer, with a particular emphasis on immune checkpoint molecules, involved in CRC pathogenesis.